文献速递心律失常心力衰竭与心肌病

瑞士房颤队列中的患者聚类与费用轨迹

Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort.
PubMed 文献 · Heart · 2023-04-25

瑞士-AF前瞻性队列研究纳入2415例房颤患者,对其中1024例有理赔数据者随访中位3.24年,年均房颤归因费用为5679瑞士法郎并保持稳定;层次聚类识别出心血管型、孤立症状型和严重病态无心血管病型三个费用特征不同的患者聚类。

要点

  • 房颤归因年均费用为5679瑞士法郎,以住院和门诊房颤治疗费用为主。
  • 心血管型与严重病态无心血管病型费用相似且较高,孤立症状型费用最低。
  • 患者聚类可用于临床和经济研究的费用分层。

核心结论

  • 房颤患者可分为三个费用特征明确的聚类,其费用轨迹有助于预判未来房颤相关医疗费用。

研究设计与样本

  • 瑞士-AF前瞻性队列研究于2014至2017年纳入2415例不同房颤病程患者,对基线特征进行层次聚类分析。
  • 其中1024例有理赔数据者纳入费用分析,中位随访3.24年(IQR 1.09年),并开发算法将费用归因于房颤及相关并发症。

主要发现

  • 年均房颤归因费用为5679瑞士法郎(5163欧元),在整个观察期内保持稳定。
  • 房颤归因费用主要由住院和门诊房颤治疗费用构成(4078瑞士法郎;3707欧元),其次为出血费用(696瑞士法郎;633欧元)和心力衰竭费用(494瑞士法郎;449欧元)。
  • 层次分析识别出三个聚类:心血管型(CV;有理赔数据N=253)、孤立症状型(IS;N=586)和严重病态无心血管病型(SM;N=185)。
  • CV聚类和SM聚类在所有费用结局上均显示相似的高费用,IS患者费用最低。

临床怎么用

  • 可利用三个患者聚类对房颤患者进行费用分层,辅助临床和经济研究设计。
  • 关注与归因费用相关的患者特征及费用轨迹,有助于早期预判房颤相关医疗费用规模。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evidence on long-term costs of atrial fibrillation (AF) and associated factors is scarce. As part of the Swiss-AF prospective cohort study, we aimed to characterise AF costs and their development over time, and to assess specific patient clusters and their cost trajectories. METHODS: Swiss-AF enrolled 2415 patients with variable duration of AF between 2014 and 2017. Patient clusters were identified using hierarchical cluster analysis of baseline characteristics. Ongoing yearly follow-ups include health insurance clinical and claims data. An algorithm was developed to adjudicate costs to AF and related complications. RESULTS: A subpopulation of 1024 Swiss-AF patients with available claims data was followed up for a median (IQR) of 3.24 (1.09) years. Average yearly AF-adjudicated costs amounted to SFr5679 (€5163), remaining stable across the observation period. AF-adjudicated costs consisted mainly of inpatient and outpatient AF treatment costs (SFr4078; €3707), followed by costs of bleeding (SFr696; €633) and heart failure (SFr494; €449). Hierarchical analysis identified three patient clusters: cardiovascular (CV; N=253 with claims), isolated-symptomatic (IS; N=586) and severely morbid without cardiovascular disease (SM; N=185). The CV cluster and SM cluster depicted similarly high costs across all cost outcomes; IS patients accrued the lowest costs. CONCLUSION: Our results highlight three well-defined patient clusters with specific costs that could be used for stratification in both clinical and economic studies. Patient characteristics associated with adjudicated costs as well as cost trajectories may enable an early understanding of the magnitude of upcoming AF-related healthcare costs.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Aebersold H, Serra-Burriel M, Foster-Wittassek F, et al. Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort. Heart. 2023. PMID: 36332981. doi:10.1136/heartjnl-2022-321520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。